Pulmonary Hypertension Association (PHA) staff and medical leadership presented research findings and interacted with global health care professionals with an interest in pulmonary hypertension (PH) at the American Thoracic Society (ATS) International Conference this week in Dallas. Michael Gray, vice president of quality care and research, shared research findings of current trends among physicians
The Pulmonary Hypertension Association’s (PHA’s) The Right Heart blog brings you a story chronicling just how rigorous, uncertain and time consuming the road to a proper pulmonary hypertension (PH) diagnosis can be. Just ask this week’s contributor to the blog, Gail Merz, who has experienced her share of difficulties along her journey. As if
Women with pulmonary hypertension (PH) deal with a host of different issues including family planning, dating and relationships and self-image. Because these topics can be difficult to discuss, the 2019 PHPN Symposium for health care professionals, “Influencing the Practice: The Art and Science of Treating Pulmonary Hypertension,” Sept. 5-7 in Washington, D.C., will feature
On May 11, the 10th and final “RACE 2 CURE PH – Taylor Caffrey Memorial 5K Run/Walk” took place in Anaheim Hills, Calif., organized by Taylor’s parents, Shari and Michael Caffrey. “In a brief 4 ½ years, Taylor brought so much to our lives and touched so many people,” says Shari. Taylor was fondly
Tracy Espinosa of Stockton, Calif., knows first-hand the need for better diagnosis and treatment of pulmonary hypertension (PH), especially when it comes to pediatric PH. Tracy lost her husband to PH and her two daughters, Lauren and TJ, now live with the disease. In late 2018, after the devastating loss of a friend’s young
"I live day to day never knowing what the day will bring to me... I just thank the Lord every day for giving me the day and pray for one more." "I resided in the metropolitan Atlanta area from 1950 till 2013. My husband and I then moved to Rochester, Minn. In or
The Pulmonary Hypertension Association (PHA) is recognizing both World PH Day and Lupus Awareness Month throughout the month of May. Lupus is a long-term autoimmune disease in which the body's immune system becomes hyperactive and attacks normal, healthy tissue. Symptoms include inflammation, swelling and damage to the joints, skin, kidneys, blood, heart and lungs.
At the end of March, the Food and Drug Administration (FDA) approved four generic versions of ambrisentan, the pulmonary arterial hypertension-targeted therapy marketed as the brand name Letairis®. All the new generic ambrisentan products (and Letairis) will be available through specialty pharmacies. At least one will also be available at retail locations. REMS Enrollment
The Pulmonary Hypertension Association’s (PHA’s) PHPN Symposium, “Influencing the Practice: The Art and Science of Treating Pulmonary Hypertension,” Sept. 5-7, will feature a “limerick showdown” between Robert P. (Bob) Frantz, M.D., and Victor F. “Vic” Tapson, M.D. The two physicians will debate the hot topic, “To Treat or Not Treat mPAP of 20-24.” Dr.
Despite being diagnosed with idiopathic pulmonary arterial hypertension as an infant in the mid-80s, Sarah Atkinson lived a happy childhood. “She rode her bike, swam in the pool, we traveled a little and she tortured her siblings…Sarah could surprise others with unexpected acts of love, such as rubbing my forehead when I wasn't feeling
